Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grace Hyun

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Plos One|November 10, 2017
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung diseaseViktor Martyanov, Grace-Hyun J Kim, Wendy Hayes, et al.
Neuro-Oncology|November 9, 2021
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenibBenjamin M Ellingson, Grace Hyun J Kim, Matt Brown, et al.
Arthritis Care & Research|August 4, 2025
International Investigation of the Gut-Lung Axis in Systemic Sclerosis-Interstitial Lung DiseaseKristofer Andréasson, Arissa Young, Swapna Joshi, et al.
Transplantation|September 17, 2021
Quantitative Image Analysis at Chronic Lung Allograft Dysfunction Onset Predicts MortalityS Samuel Weigt, Grace-Hyun J Kim, Heather D Jones, et al.
American Journal of Respiratory and Critical Care Medicine|June 6, 2024
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical TrialLisa Lancaster, Vincent Cottin, Murali Ramaswamy, et al.
Rheumatology (Oxford, England)|September 2, 2024
Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung diseaseSangmee Sharon Bae, Daniela Markovic, Didem Saygin, et al.
Therapeutic Advances in Respiratory Disease|November 8, 2024
Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF studyLisa Lancaster, Vincent Cottin, Murali Ramaswamy, et al.
ACR Open Rheumatology|November 26, 2025
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialDinesh Khanna, Cathie Spino, Donald P Tashkin, et al.
American Journal of Respiratory and Critical Care Medicine|December 19, 2023
Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop ReportSydney B Montesi, Christian R Gomez, Michael Beers, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Plos One|November 10, 2017
Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung diseaseViktor Martyanov, Grace-Hyun J Kim, Wendy Hayes, et al.
Neuro-Oncology|November 9, 2021
Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenibBenjamin M Ellingson, Grace Hyun J Kim, Matt Brown, et al.
Arthritis Care & Research|August 4, 2025
International Investigation of the Gut-Lung Axis in Systemic Sclerosis-Interstitial Lung DiseaseKristofer Andréasson, Arissa Young, Swapna Joshi, et al.
Transplantation|September 17, 2021
Quantitative Image Analysis at Chronic Lung Allograft Dysfunction Onset Predicts MortalityS Samuel Weigt, Grace-Hyun J Kim, Heather D Jones, et al.
American Journal of Respiratory and Critical Care Medicine|June 6, 2024
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical TrialLisa Lancaster, Vincent Cottin, Murali Ramaswamy, et al.
Rheumatology (Oxford, England)|September 2, 2024
Associations between 6-minute walk distance and physiologic measures and clinical outcomes in myositis-associated interstitial lung diseaseSangmee Sharon Bae, Daniela Markovic, Didem Saygin, et al.
Therapeutic Advances in Respiratory Disease|November 8, 2024
Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF studyLisa Lancaster, Vincent Cottin, Murali Ramaswamy, et al.
ACR Open Rheumatology|November 26, 2025
Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialDinesh Khanna, Cathie Spino, Donald P Tashkin, et al.
American Journal of Respiratory and Critical Care Medicine|December 19, 2023
Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop ReportSydney B Montesi, Christian R Gomez, Michael Beers, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
Pageof 10